Patents by Inventor Andreas Alphons Franciscus Ludovicus Van Puijenbroek

Andreas Alphons Franciscus Ludovicus Van Puijenbroek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MiRNA for treating diseases and conditions associated with neo-angiogenesis
    Patent number: 10023868
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 17, 2018
    Assignee: INTERNA TECHNOLOGIES B.V.
    Inventors: Sanne Weijzen, Roeland Quirinus Jozef Schaapveld, Meriem Bourajjaj, Rick Jan Van Haastert, Arjan Willem Griffioen, Judith Rosina Van Beijnum, Edwin Pieter Johan Gerard Cuppen, Eugene Berezikov, Andreas Alphons Franciscus Ludovicus Van Puijenbroek, Willemijn Maria Gommans, Negar Babae, Petronella Innocentia Van Noort
  • MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT
    Patent number: 9944932
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: April 17, 2018
    Assignee: INTERNA TECHNOLOGIES B.V.
    Inventors: Roeland Quirinus Jozef Schaapveld, Gerardus Wilhelmus Christiaan Theodoor Verhaegh, Jacobus Antonius Schalken, Andreas Alphons Franciscus Ludovicus van Puijenbroek, Willemijn Maria Gommans, Sanne Weijzen
  • MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT
    Publication number: 20160017338
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).
    Type: Application
    Filed: September 10, 2015
    Publication date: January 21, 2016
    Applicant: INTERNA TECHNOLOGIES B.V.
    Inventors: Roeland Quirinus Jozef SCHAAPVELD, Gerardus Wilhelmus Christiaan Theodoor VERHAEGH, Jacobus Antonius SCHALKEN, Andreas Alphons Franciscus Ludovicus van PUIJENBROEK, Willemijn Maria GOMMANS, Sanne WEIJZEN
  • MiRNA for Treating Diseases and Conditions Associated with Neo-angiogenesis
    Publication number: 20140005251
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 2, 2014
    Applicant: InteRNA Technologies B.V.
    Inventors: Sanne WEIJZEN, Roeland Quirinus Jozef SCHAAPVELD, Meriem BOURAJJAJ, Rick Jan VAN HAASTERT, Arjan Willem GRIFFIOEN, Judith Rosina VAN BEIJNUM, Edwin Pieter Johan Gerard CUPPEN, Eugene BEREZIKOV, Andreas Alphons Franciscus Ludovicus VAN PUIJENBROEK, Willemijn Maria GOMMANS, Negar BABAE, Petronella Innocentia VAN NOORT
  • MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
    Publication number: 20130072545
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).
    Type: Application
    Filed: September 4, 2012
    Publication date: March 21, 2013
    Applicant: InteRNA Technologies B.V.
    Inventors: Roeland Quirinus Jozef Schaapveld, Gerardus Wilhelmus Christiaan Theodoor Verhaegh, Jacobus Antonius Schalken, Andreas Alphons Franciscus Ludovicus Van Puijenbroek, Willemjin Maria Gommans, Sanne Weijzen